Can we freeze them? Yes we can, says Nkarta
The company is now in the clinic, claiming to have cleared one of the biggest hurdles blocking development of an NK cell therapy.
Ash 2020 movers – shorts roasting on an open fire
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.
Ash 2020 cell therapy preview – the battle for recognition
With many of the usual targets on display Fate, Celyad, Allovir and others look to maintain momentum.
Kiadis makes nothing into €325m
Sanofi goes all in on Kiadis's natural killer cell projects, gained through an all-stock deal in 2019.
Global Blood aims for sickle cell dominance
Global Blood punching above its weight in sickle cell as 2022 sales forecasts for voxelotor hit $529m in 2022.